The introduction and implementation of Reporting and Data Systems (RADS) offers clinicians a variety of benefits to how they are able to deliver care in a clinical setting. These systems present a method for the standardized reporting of images of numerous internal organ systems, and help clinicians structure and remove ambiguity from findings from cancer imaging reports. These systems also enable for data to be audited in a much more straightforward manner, and permit sharing of findings between clinicians in different departments.
RADS are becoming increasingly commonplace in cancer care premises, and an everyday tool for radiologists involved in cancer care. The number of organ specific cancers benefitting from RADS continues to grow, but currently covers breast cancers (BI-RADS), colon cancers (C-RADS), liver cancer (LI-RADS), head and neck cancers (NI-RADS), prostate cancer (P-RADS), and others. Each of these organ specific systems is decided upon by groups of specialists in each respective field, and are updated regularly as required to ensure optimized diagnostic parameters are utilized. Each system makes use of a stepwise numerical scoring system which grades the cancer in question with regards to the clinical suspicion around the tumor identified by the radiologist.
This Research Topic invites submissions which demonstrate how RADS benefit cancer patients, and how improvements to these systems can further benefit patients and optimize disease outcomes. Submissions may concern aforementioned aspects of RADS and how they benefit patients, or divulge aspects addressing, but not limited to, identification of negative or inadequate data input to the systems, the use of these systems to identify microvascular invasion, treatment success/failure, findings secondary to the focal cancer diagnosis, all of which should demonstrably benefit the patient, or alternatively identify shortcomings which need to be addressed moving forward.
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
The introduction and implementation of Reporting and Data Systems (RADS) offers clinicians a variety of benefits to how they are able to deliver care in a clinical setting. These systems present a method for the standardized reporting of images of numerous internal organ systems, and help clinicians structure and remove ambiguity from findings from cancer imaging reports. These systems also enable for data to be audited in a much more straightforward manner, and permit sharing of findings between clinicians in different departments.
RADS are becoming increasingly commonplace in cancer care premises, and an everyday tool for radiologists involved in cancer care. The number of organ specific cancers benefitting from RADS continues to grow, but currently covers breast cancers (BI-RADS), colon cancers (C-RADS), liver cancer (LI-RADS), head and neck cancers (NI-RADS), prostate cancer (P-RADS), and others. Each of these organ specific systems is decided upon by groups of specialists in each respective field, and are updated regularly as required to ensure optimized diagnostic parameters are utilized. Each system makes use of a stepwise numerical scoring system which grades the cancer in question with regards to the clinical suspicion around the tumor identified by the radiologist.
This Research Topic invites submissions which demonstrate how RADS benefit cancer patients, and how improvements to these systems can further benefit patients and optimize disease outcomes. Submissions may concern aforementioned aspects of RADS and how they benefit patients, or divulge aspects addressing, but not limited to, identification of negative or inadequate data input to the systems, the use of these systems to identify microvascular invasion, treatment success/failure, findings secondary to the focal cancer diagnosis, all of which should demonstrably benefit the patient, or alternatively identify shortcomings which need to be addressed moving forward.
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
